Larotrectinib
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors
What's the purpose of the trial?
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C29.707199%2C-95.396698&zoom=10)
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Larotrectinib is a first generation tropomyosin kinase (TRK) inhibitor used in the treatment of cancers that have TRK fusions.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.